[Progressive multifocal leukoencephalopathy in a patient with multiple myeloma]
Related Experiment Video
Updated: Apr 19, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Cecilie Balslev Willert1, Frederik Neess Engsig, Helle Wulf Eskildsen
1Dagmarsgade 10, 3. th., 2200 København N. ceciliebwi@gmail.com.
Abstract:
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease in the central nervous system. It is caused by reactivation of John Cunningham-virus and has a grave prognosis. PML occurs most frequently in HIV-patients, but can also be seen in patients with iatrogenic immunodeficiency. Here, we present a patient with multiple myeloma and cardiac amyloidosis who developed PML after receiving treatment with several chemotherapeutics. This case report underlines the importance of bearing PML in mind when immunocompromised patients develop diffuse neurological symptoms.
Insights
Progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by John Cunningham virus reactivation, can occur in immunocompromised patients. This case highlights PML in a multiple myeloma patient treated with chemotherapy, emphasizing its importance in diagnosing neurological symptoms.
Area of Science:
- Neuroimmunology
- Neurology
- Oncology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, severe demyelinating disease of the central nervous system.
- PML is caused by the reactivation of the John Cunningham virus (JCV).
- It most commonly affects individuals with HIV/AIDS but can also occur in those with iatrogenic immunodeficiency.
Observation:
- A patient with multiple myeloma and cardiac amyloidosis developed PML.
- The patient had received multiple chemotherapeutic agents.
- This presentation occurred in the context of iatrogenic immunodeficiency.
Findings:
- This case report details a rare instance of PML in a patient with multiple myeloma and cardiac amyloidosis.
- The development of PML was associated with chemotherapy treatment.
- The patient exhibited diffuse neurological symptoms.
Implications:
- Highlights the importance of considering PML in the differential diagnosis of neurological symptoms in immunocompromised patients.
- Underscores the potential risk of PML in patients undergoing chemotherapy, particularly those with underlying conditions like multiple myeloma.
- Emphasizes the need for vigilance in recognizing PML in diverse immunocompromised populations beyond HIV/AIDS.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Related Concept Videos
Multiple Sclerosis l: Introduction
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Encephalitis l: Introduction
Hepatic Encephalopathy